CN1265592A - 减少mcp－1蛋白产生的活性药性组合物 - Google Patents
减少mcp－1蛋白产生的活性药性组合物 Download PDFInfo
- Publication number
- CN1265592A CN1265592A CN98807694A CN98807694A CN1265592A CN 1265592 A CN1265592 A CN 1265592A CN 98807694 A CN98807694 A CN 98807694A CN 98807694 A CN98807694 A CN 98807694A CN 1265592 A CN1265592 A CN 1265592A
- Authority
- CN
- China
- Prior art keywords
- mcp
- pharmaceutical composition
- disease
- protein
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100021943 C-C motif chemokine 2 Human genes 0.000 title claims abstract description 27
- 101710155857 C-C motif chemokine 2 Proteins 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 206010058046 Post procedural complication Diseases 0.000 claims description 3
- 208000035965 Postoperative Complications Diseases 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000007529 inorganic bases Chemical class 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 239000005482 chemotactic factor Substances 0.000 description 7
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 5
- 229960005149 bendazac Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000003725 endotheliocyte Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- -1 (1-benzyl-1-indazole-3-yl) ethoxyacetic acid Chemical compound 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 108010055204 Chemokine CCL8 Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- UEFYLLXITIWCEG-UHFFFAOYSA-N N1N=CC2=CC=CC=C12.[O] Chemical compound N1N=CC2=CC=CC=C12.[O] UEFYLLXITIWCEG-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
式(Ⅰ)化合物和其与药物可接受的有机或无机碱的盐在制备治疗以MCP－1蛋白产生为特征的疾病的活性药物组合物中的用途。
Description
本发明涉及吲唑氧基链烷酸在制备治疗以MCP-1蛋白产生为特征的疾病的活性药物组合物中的用途。
美国专利3470194描述了具有抗炎活性并称为苄达酸(bendazac)的下式(1-苄基-1-吲唑-3-基)氧基乙酸。
另外，已知苄达酸和其与药物可接受碱的盐被用于治疗一些异常脂血症(US4352813)、色素性视网膜炎(EP-B-131317)和白内障(US4451477)。
苄达酸和其盐被批露用于预防接触透镜的浑浊化(EP255967)。
现已发现具有式(I)结构的化合物还在减少MCP-1蛋白产生中具有活性。
如所知，MCP-1蛋白(单核细胞趋化性蛋白-1)为属于趋化因子β亚家族的趋化因子。它对单核细胞具有强的趋化活性并作用于T淋巴细胞、肥大细胞和嗜碱性细胞。
属于β亚家族的其它趋化因子为例如MCP-2(单核细胞趋化蛋白-2)、MCP-3、MCP-4、MIP-1α、MIP-1β、RANTES和蛋白1309。
β亚家族在结构上不同于α亚家族；事实上，α亚家族的趋化因子的前面两个半胱氨酸被插入的氨基酸隔开，而β亚家族趋化因子的前面两个半胱氨酸却是彼此相邻的。MCP-1由数种类型的细胞(白细胞、血小板、成纤维细胞和内皮细胞)产生。
在所有已知的趋化因子中，MCP-1对于单核细胞和巨噬细胞显示最高的特异性，它对于它们不仅是一个吸引因子，而且是激活刺激剂，因此诱导产生过氧化物和花生四烯酸的过程，以及刺激吞噬细胞活性的放大。
通常趋化因子尤其是MCP-1的分泌常常由许多因子诱导，如白介素-1(IL-1)、白介素-2(IL-2)、TNFα(肿瘤坏死因子α)、γ-干扰素和细菌脂多糖(LPS)。
在人体中，MCP-1在许多被传统医学分在不同类别中的急性或慢性疾病中发现：例如间质性肺疾病(ILD)、脉管炎和动脉粥样硬化，和肾病，例如肾炎、肾炎综合症、特征为进行性增生的膜性或膜增生性肾小球肾炎的肾病。
在间质性肺疾病中，由肺内皮细胞释放的MCP-1吸引和激活感受态细胞，结果释放损伤肺的肺泡结构的介质。
在脉管炎中，在有害刺激后，MCP-1由脉管的内皮细胞释放，并且吸引和激活导致管壁损伤的单核细胞和其它细胞类型。
在动脉粥样硬化中，在血管平滑肌细胞损伤后，MCP-1由血管内皮细胞产生。MCP-1吸引单核细胞，使其起初粘附于动脉壁、接着迁移穿过血管壁，通过刺激平滑肌细胞的增殖导致动脉粥样化的形成。
在肾病中，致病机理特征是激素和细胞因子的活化，这些因子导致对肾小球和肾小管损伤的开始。尤其是，起始事件几乎总是以白细胞对肠的侵润为特征。这种现象被可溶性因子引发并控制，其中由于对单核细胞和巨噬细胞具有高特异性的趋化蛋白特征，MCP-1在该疾病中发挥重要的作用。
由于它们在病理学现象的上游起作用，目前用于这些疾病的疗法是非特异性，并且经常具有许多有时是非常严重的副作用。
而且上述疗法仅能获得暂时对病理现象的缓和，另一方面它们的高毒性阻碍了它们用于在慢性疾病中所必需的长期治疗。
尤其对于动脉粥样硬化，目前使用的药物仅对一些与形成动脉粥样化有关的因素起作用，如高胆固醇血症或高血压，而对病理过程的靶子即血管壁不起作用。
总的来说趋化因子尤其是MCP-1在手术介入后发生并发症的情况中也非常重要，例如血管成形术、动脉粥样硬化切除术、循环修复术、移植、器官置换、组织置换和假体植入。这些并发症的发生通常使得病人必需进行进一步深入的治疗或甚至是新的手术。
US5571713公开了体外抑制人单核细胞和平滑肌产生MCP-1的包含MCP-1反义寡核苷酸的组合物。
因此，仍强烈需要一种药物组合物，用于有效治疗以MCP-1产生为特征的疾病，例如动脉粥样硬化、脉管炎、间质性肺病、肾病、及心血管手术、移植或器官或组织置换和假体植入中的术后并发症。
因此，本发明的一个目的是提供下式的(1-苄基-1H-吲唑-3-基)氧基乙酸(苄达酸)和其与药物可接受有机或无机碱的盐
在制备治疗以MCP-1蛋白产生为特征的疾病的活性药物组合物中的用途。
以MCP-1蛋白产生为特征的疾病的典型实例为：动脉粥样硬化、脉管炎、间质性肺病、肾病、和心血管手术、移植或器官组织置换和假体植入的术后并发症。
优选地，本发明的药物组合物被制备成适宜的剂型，其中包含有效剂量的至少一种式(I)化合物或其与药物可接受有机或无机碱的盐和至少一种药物可接受的惰性成分。
适宜剂型的实例为用于口服给药的片剂、胶囊、包衣片剂、颗粒剂、溶液剂和糖浆；用于透皮给药的膏药贴片；用于直肠给药的栓剂和通过注射、气雾剂或眼途径给药的溶液剂。
其它适宜的剂型为用于口服或注射途径的缓释和脂质体形式。
制剂中还可包含其它常规成分，例如：稳定保存剂、表面活性剂、缓冲剂、调节渗透压的盐、乳化剂、甜味剂、着色剂、香味剂等。
如果特定的治疗需要，本发明的药物组合物可包含共同给药时对治疗有用的其它药理活性成分。
本发明的药物组合物中的式(I)化合物或其与药物可接受碱的盐的量可在宽范围内变化，其取决于已知的因素，例如所治疗疾病的类型、疾病的严重性、病人的体重、剂型、选择的给药途径、每天给药的次数和选择的式(I)化合物的功效。然而，本领域技术人员可容易地并常规性地确定其最佳量。
通常，本发明的药物组合物中的式(I)化合物或其与药物可接受碱的盐的量为确保给药水平为1-100mg/kg/天的量。优选给药水平为5-50mg/kg/天或更优选2-20mg/kg天。
本发明药物组合物的剂型可根据药剂师已知的技术制备，包括混合、成粒、压制、溶解、灭菌等。
本发明组合物的活性可通过下面的试验评价。
试验I
药物对MCP-1产生的影响
评价了药物降低LPS刺激的白细胞(PBMC)产生MCP-1的能力。通过在Ficoll梯度中离心分离白细胞，接着在存在或不存在标量浓度的待评价药物下用LPS刺激。最后收集上清液并通过特异性免疫酶试验测定MCP-1的水平。
试验II
药物对小鼠“气囊”中的细胞吸引的影响
在小鼠实验模型中研究了药物的作用，所述模型特征在于产生MCP-1、细胞浸润和渗出物的形成。用啮齿动物标准食物或用加入了待评价药物的相同食物以随意食水方式喂养小鼠。醚麻醉下，将无菌空气注射至小鼠的背侧皮肤以形成一个囊。将无菌的生理溶液或刺激剂注射至如此形成的囊中。所述刺激剂可为角叉菜或IL-1。用CO2窒息杀死小鼠。收集产生的渗出液并用于白细胞计数以及所产生介质的测定。
Claims (2)
1.式(I)化合物和其与药物可接受的有机或无机碱的盐
在制备治疗以MCP-1蛋白产生为特征的疾病的活性药物组合物中的用途。
2.根据权利要求1的式(I)化合物的用途，其特征在于以MCP-1蛋白产生为特征的疾病选自动脉粥样硬化、脉管炎、间质性肺病、肾病、和心血管手术、移植或器官或组织置换和假体植如的术后并发症。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI001788A IT1293794B1 (it) | 1997-07-28 | 1997-07-28 | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| ITMI97A01788 | 1997-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1265592A true CN1265592A (zh) | 2000-09-06 |
Family
ID=11377641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98807694A Pending CN1265592A (zh) | 1997-07-28 | 1998-07-22 | 减少mcp－1蛋白产生的活性药性组合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6191158B1 (zh) |
| EP (1) | EP0999836A1 (zh) |
| JP (1) | JP2001510802A (zh) |
| KR (1) | KR20010022333A (zh) |
| CN (1) | CN1265592A (zh) |
| AU (1) | AU9160298A (zh) |
| BG (1) | BG104162A (zh) |
| CA (1) | CA2298507A1 (zh) |
| EA (1) | EA200000168A1 (zh) |
| HU (1) | HUP0004936A3 (zh) |
| IL (1) | IL134050A0 (zh) |
| IT (1) | IT1293794B1 (zh) |
| SK (1) | SK1332000A3 (zh) |
| TR (1) | TR200000244T2 (zh) |
| WO (1) | WO1999004791A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20062254A1 (it) | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3970194A (en) * | 1975-01-08 | 1976-07-20 | Philip Morris Incorporated | Razor blade cartridge and display article |
| IT1147079B (it) * | 1980-05-30 | 1986-11-19 | Sigma Tau Ind Farmacuetiche Ri | Esteri di alcossi-acil derivati della carnitina procedimento per la loro preparatione e composizioni farmaceutiche che li contengono |
| IT1131779B (it) * | 1980-07-29 | 1986-06-25 | Acraf | Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione |
| IT1189052B (it) * | 1981-11-27 | 1988-01-28 | Acraf | Trattamento della cataratta |
| IT1197805B (it) * | 1986-08-01 | 1988-12-06 | Acraf | Metodo per il tratamento di lenti a contatto |
-
1997
- 1997-07-28 IT IT97MI001788A patent/IT1293794B1/it active IP Right Grant
-
1998
- 1998-07-22 CA CA002298507A patent/CA2298507A1/en not_active Abandoned
- 1998-07-22 IL IL13405098A patent/IL134050A0/xx unknown
- 1998-07-22 EP EP98943863A patent/EP0999836A1/en not_active Withdrawn
- 1998-07-22 HU HU0004936A patent/HUP0004936A3/hu unknown
- 1998-07-22 KR KR1020007000912A patent/KR20010022333A/ko not_active Application Discontinuation
- 1998-07-22 CN CN98807694A patent/CN1265592A/zh active Pending
- 1998-07-22 SK SK133-2000A patent/SK1332000A3/sk unknown
- 1998-07-22 AU AU91602/98A patent/AU9160298A/en not_active Abandoned
- 1998-07-22 JP JP2000503846A patent/JP2001510802A/ja active Pending
- 1998-07-22 US US09/463,665 patent/US6191158B1/en not_active Expired - Fee Related
- 1998-07-22 EA EA200000168A patent/EA200000168A1/ru unknown
- 1998-07-22 WO PCT/EP1998/004925 patent/WO1999004791A1/en not_active Application Discontinuation
- 1998-07-22 TR TR2000/00244T patent/TR200000244T2/xx unknown
-
2000
- 2000-02-17 BG BG104162A patent/BG104162A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0004936A3 (en) | 2002-01-28 |
| TR200000244T2 (tr) | 2000-09-21 |
| KR20010022333A (ko) | 2001-03-15 |
| EP0999836A1 (en) | 2000-05-17 |
| IL134050A0 (en) | 2001-04-30 |
| ITMI971788A1 (it) | 1999-01-28 |
| BG104162A (en) | 2000-12-29 |
| IT1293794B1 (it) | 1999-03-10 |
| HUP0004936A2 (hu) | 2001-11-28 |
| SK1332000A3 (en) | 2000-12-11 |
| AU9160298A (en) | 1999-02-16 |
| EA200000168A1 (ru) | 2000-08-28 |
| WO1999004791A1 (en) | 1999-02-04 |
| JP2001510802A (ja) | 2001-08-07 |
| US6191158B1 (en) | 2001-02-20 |
| CA2298507A1 (en) | 1999-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5086322B2 (ja) | Ｍｃｐ−１プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物 | |
| DE69434490T2 (de) | Zusammenstellungen zur Krebsbehandlung | |
| CN1356908A (zh) | 包含低分子量凝血酶抑制剂及其药物前体的药用制剂 | |
| CN1265592A (zh) | 减少mcp－1蛋白产生的活性药性组合物 | |
| EP1469853B1 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-d-pyrimidine for treating of urinary incontinence | |
| Tiegs et al. | Colchicine prevents tumor necrosis factor-induced toxicity in vivo | |
| US7015202B2 (en) | Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors | |
| Berman et al. | Inhibition of dermal fibrosis by interferons | |
| Sebel et al. | Respiratory depression after alfentanil infusion. | |
| JP4381495B2 (ja) | 有機ゲルマニウム化合物を有効成分とするｍｃｐ−１受容体拮抗剤、及びｍｃｐ−１が関与する炎症性疾患及び臓器障害の発症予防または治療剤 | |
| CN110664807B (zh) | 一种具有协同抗黑色素瘤功效的药物组合物及其应用 | |
| CN1149995C (zh) | 喹唑啉酮类化合物在制药中的用途 | |
| US20060246054A1 (en) | Bromelain preparation and pharmaceutical composition containing the same | |
| JP3587851B2 (ja) | Ｔｎｆ誘発病状の治療におけるベンジダミンの使用 | |
| JP2006335678A (ja) | 改良されたブロメライン製剤およびそれを含む医薬組成物 | |
| WO2007074727A1 (ja) | 口腔カンジダ症治療剤 | |
| CN115300516A (zh) | 一种治疗类风湿性关节炎的药用组合物及其应用 | |
| Choi et al. | OK205 regulates production of inflammatory cytokines in HMC-1 cells | |
| CN117100754A (zh) | Vps34抑制剂在制备防治蒽环类药物诱导心脏毒性的药物中的应用 | |
| CN110833547A (zh) | 吡唑并嘧啶衍生物在治疗类风湿关节炎的用途 | |
| WO2003086302A2 (en) | Propagermanium for treating myeloma bone disease and other bone disorders | |
| Fleischmann et al. | ANAKINRA: A NOVEL BIOLOGICAL THERAPY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS. | |
| JP2003081839A (ja) | トレハロースを含有する免疫賦活剤 | |
| CN1370534A (zh) | 一种治疗多囊肾病的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |